608 related articles for article (PubMed ID: 12592224)
61. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
62. Barrett's esophagus.
Bonino JA; Sharma P
Curr Opin Gastroenterol; 2005 Jul; 21(4):461-5. PubMed ID: 15930989
[TBL] [Abstract][Full Text] [Related]
63. Etiology of Barrett's metaplasia and esophageal adenocarcinoma.
Kim R; Weissfeld JL; Reynolds JC; Kuller LH
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):369-77. PubMed ID: 9149898
[TBL] [Abstract][Full Text] [Related]
64. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
65. Barrett's Esophagus and esophageal adenocarcinoma.
Bresalier RS
Annu Rev Med; 2009; 60():221-31. PubMed ID: 18783330
[TBL] [Abstract][Full Text] [Related]
66. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
67. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
[TBL] [Abstract][Full Text] [Related]
68. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends.
Cooper GS; Kou TD; Chak A
Am J Gastroenterol; 2009 Jun; 104(6):1356-62. PubMed ID: 19491849
[TBL] [Abstract][Full Text] [Related]
69. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
70. [Adenocarcinoma of the gastro-esophagus junction associated to endobrachyesophagus. Two case reports. Review of the literature].
Kreiker J; Daou R
J Med Liban; 2004; 52(2):103-10. PubMed ID: 15884690
[TBL] [Abstract][Full Text] [Related]
71. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.
Abela JE; Going JJ; Mackenzie JF; McKernan M; O'Mahoney S; Stuart RC
Am J Gastroenterol; 2008 Apr; 103(4):850-5. PubMed ID: 18371135
[TBL] [Abstract][Full Text] [Related]
72. Is Barrett's metaplasia the source of adenocarcinomas of the cardia?
Clark GW; Smyrk TC; Burdiles P; Hoeft SF; Peters JH; Kiyabu M; Hinder RA; Bremner CG; DeMeester TR
Arch Surg; 1994 Jun; 129(6):609-14. PubMed ID: 8204035
[TBL] [Abstract][Full Text] [Related]
73. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).
Rugge M; Zaninotto G; Parente P; Zanatta L; Cavallin F; Germanà B; Macrì E; Galliani E; Iuzzolino P; Ferrara F; Marin R; Nisi E; Iaderosa G; Deboni M; Bellumat A; Valiante F; Florea G; Della Libera D; Benini M; Bortesi L; Meggio A; Zorzi MG; Depretis G; Miori G; Morelli L; Cataudella G; d'Amore ES; Franceschetti I; Bozzola L; Paternello E; Antonini C; Di Mario F; Dal Bò N; Furlanetto A; Norberto L; Polese L; Iommarini S; Farinati F; Battaglia G; Diamantis G; Realdon S; Guido E; Mastropaolo G; Canova D; Guerini A; Franceschi M; Zirillo M
Ann Surg; 2012 Nov; 256(5):788-94; discussion 794-5. PubMed ID: 23095623
[TBL] [Abstract][Full Text] [Related]
74. The histologic squamo-oxyntic gap: an accurate and reproducible diagnostic marker of gastroesophageal reflux disease.
Chandrasoma P; Wijetunge S; Demeester SR; Hagen J; Demeester TR
Am J Surg Pathol; 2010 Nov; 34(11):1574-81. PubMed ID: 20871393
[TBL] [Abstract][Full Text] [Related]
75. [Epidemiology and pathophysiology of Barrett esophagus].
Freys SM; Fuchs KH; Heimbucher J; Fein M; Thiede A
Zentralbl Chir; 2000; 125(5):406-13. PubMed ID: 10929624
[TBL] [Abstract][Full Text] [Related]
76. Barrett's esophagus. Update of pathophysiology and management.
Oberg S; Clark GW; DeMeester TR
Hepatogastroenterology; 1998; 45(23):1348-56. PubMed ID: 9840064
[TBL] [Abstract][Full Text] [Related]
77. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
78. Prevalence of Barrett's esophagus in the general population: an endoscopic study.
Ronkainen J; Aro P; Storskrubb T; Johansson SE; Lind T; Bolling-Sternevald E; Vieth M; Stolte M; Talley NJ; Agréus L
Gastroenterology; 2005 Dec; 129(6):1825-31. PubMed ID: 16344051
[TBL] [Abstract][Full Text] [Related]
79. Molecular biology of Barrett's cancer.
Atherfold PA; Jankowski JA
Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163
[TBL] [Abstract][Full Text] [Related]
80. [Gastroesophageal reflux disease and malignancy].
Richert Z; Robaszkiewicz M
Rev Prat; 2008 Sep; 58(13):1414-5, 1417, 1419-20. PubMed ID: 18924321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
